Results 221 to 230 of about 184,542 (286)

Synergistic Chemo-Photodynamic Therapy Based on Hollow Mesoporous Organosilica Nanoparticles for Treating Psoriasis-Like Inflammation

Zhijia Fan, Gang Zhao, Yixiao Gan, Wei Li, Rong Xia, Min Lü, Zhicheng Wang   +6 more
openalex   +1 more source

Pediatric Psoriasis: A Peek into the Comorbidity Profile.

Indian J Dermatol
Gupta S, Goel S, Chopra D, Malhan S, Sidhu AS.   +4 more
europepmc   +1 more source

Dermoscopic and Histopathological Comparison of Palmoplantar Psoriasis and Eczema: A Clinico‐Pathological Study

Sameera Boda, Metta Arun Kumar, Turpati Narayana Rao   +2 more
openalex   +1 more source

Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review. Objectives This systematic review aims to assess dermatological manifestations associated with
Nour Ghostine, Maya Halabi‐Tawil
wiley   +1 more source

Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis. [PDF]

PLoS One
Warren RB, Hunter HJA, Papp KA, Gordon KB, Tang MT, Enejosa JV, Huang KC, Raha D, Batugedara HM, Skinner C, Kobel PA, Rademacher PM, Ghilardi N, Fatheree P, Jacobsen JR, Lu TT.   +15 more
europepmc   +1 more source

Probing the Dark Chemical Matter Against PDE4 for the Management of Psoriasis Using in-Silico and in-Vivo Approach [PDF]

B Swapna, Satvik Kotha, S. Divakar, S Ramachandra Setty, A. Seetharama Acharya   +4 more
openalex   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

Immunological Antagonism Between Psoriasis and Atopic Dermatitis: Pathways, Clinical Implications, and Therapeutic Perspectives. [PDF]

Clin Cosmet Investig Dermatol
Qin J, Meng Z, Min W, Wang X, Zou Y.
europepmc   +1 more source

An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target

, 2017
Satveer K. Mahil, Marika Catapano, Paola Di Meglio, Nick Dand, Helena Ahlfors, Ian Carr, Catherine Smith, Richard C. Trembath, Mark Peakman, John Wright, Francesca D. Ciccarelli, Juliet N. Barker, Francesca Capon   +12 more
openalex   +2 more sources

Approach to Nail Pitting in Pediatric and Adolescent Patients: A Dermatology Perspective

JEADV Clinical Practice, EarlyView.
ABSTRACT This narrative review aims to discuss the etiologies of nail pitting in pediatric and adolescent patients, while providing a framework for further evaluation of possible underlying systemic conditions and their clinical findings from a dermatologic standpoint.
Elizabeth Botto, Victoria Griffith, Samuel Stahly, Jere Mammino   +3 more
wiley   +1 more source